Stock listing
Lang & Schwarz:A1W7EA Veracyte, Inc. Aktie
German listing (Lang & Schwarz) of Veracyte, Inc. · home listing NASDAQ:VCYT
Follow Veracyte, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:VCYT
$25.13 USD -0.44 (-1.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:VCYT
- Day range
- $24.53 – $25.60 USDNov 20, 2026
- Volume
- 2.79M sharesNov 20, 2026
- Market cap
- $2.03B USDAt the close on Nov 20, 2026 · price × 80.70M shares outstanding
- 52-week range
- $21.91 – $60.91 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $67.66M USDMedian day 1.37M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VCYT · Home | $25.13 USD | -0.44 (-1.7%) | 2,792,810 | $24.63 | $25.60 | $24.53 | $25.57 | Close on Nov 20, 2026 |
| Frankfurt:12V | €22.29 EUR | -1.12 (-4.8%) | — | €22.29 | €22.29 | €22.29 | €23.41 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VCYT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $25.13 | -0.44 | -1.7% | $24.63 | $25.60 | $24.53 | 2,792,810 | |
| $25.57 | +1.34 | +5.5% | $24.23 | $25.65 | $24.17 | 2,445,776 | |
| $24.23 | +0.22 | +0.9% | $23.99 | $24.47 | $23.60 | 2,920,810 | |
| $24.01 | -0.32 | -1.3% | $23.97 | $24.57 | $23.27 | 2,188,981 | |
| $24.33 | -0.30 | -1.2% | $24.60 | $24.65 | $23.47 | 2,029,307 | |
| $24.63 | -0.48 | -1.9% | $24.60 | $25.29 | $24.07 | 2,507,764 | |
| $25.11 | +1.05 | +4.4% | $25.20 | $25.84 | $24.80 | 3,339,730 | |
| $24.06 | -1.86 | -7.2% | $25.52 | $25.88 | $23.73 | 4,463,164 | |
| $25.92 | +1.76 | +7.3% | $24.40 | $26.25 | $23.80 | 5,062,907 | |
| $24.16 | +0.16 | +0.7% | $23.84 | $24.99 | $22.50 | 6,579,942 | |
| $24.00 | -28.52 | -54.3% | $29.59 | $29.79 | $21.91 | 14,972,472 | |
| $52.52 | +2.23 | +4.4% | $52.35 | $52.76 | $49.29 | 1,834,513 | |
| $50.29 | +1.29 | +2.6% | $49.95 | $51.42 | $49.88 | 1,082,104 | |
| $49.00 | -1.01 | -2.0% | $50.43 | $50.61 | $48.90 | 1,150,177 | |
| $50.01 | -2.16 | -4.1% | $51.54 | $51.93 | $49.65 | 1,015,333 | |
| $52.17 | +1.86 | +3.7% | $50.82 | $52.39 | $49.63 | 1,231,141 | |
| $50.31 | +0.03 | +0.1% | $50.00 | $51.79 | $49.87 | 1,397,992 | |
| $50.28 | +2.08 | +4.3% | $48.06 | $52.25 | $47.33 | 1,809,888 | |
| $48.20 | +0.27 | +0.6% | $48.24 | $48.96 | $47.70 | 748,098 | |
| $47.93 | +1.89 | +4.1% | $45.87 | $48.07 | $45.48 | 906,000 | |
| $46.04 | -0.18 | -0.4% | $45.98 | $46.63 | $45.29 | 1,203,500 | |
| $46.22 | +1.43 | +3.2% | $44.17 | $46.43 | $43.90 | 812,300 | |
| $44.79 | +0.99 | +2.3% | $43.91 | $45.17 | $43.47 | 1,136,400 | |
| $43.80 | +0.68 | +1.6% | $43.70 | $45.01 | $43.45 | 725,400 | |
| $43.12 | -1.27 | -2.9% | $45.00 | $45.75 | $42.83 | 2,063,200 | |
| $44.39 | +0.88 | +2.0% | $43.36 | $45.58 | $42.70 | 1,227,200 | |
| $43.51 | +0.40 | +0.9% | $42.37 | $43.99 | $42.20 | 935,300 | |
| $43.11 | -0.91 | -2.1% | $43.67 | $44.29 | $43.04 | 760,400 | |
| $44.02 | -1.21 | -2.7% | $45.18 | $45.22 | $43.29 | 1,151,600 | |
| $45.23 | +1.63 | +3.7% | $43.71 | $46.17 | $43.50 | 966,500 | |
| $43.60 | +0.44 | +1.0% | $42.50 | $43.67 | $41.22 | 1,221,600 | |
| $43.16 | -1.49 | -3.3% | $44.04 | $44.21 | $42.34 | 1,213,600 | |
| $44.65 | -3.02 | -6.3% | $48.00 | $48.84 | $44.09 | 1,730,800 | |
| $47.67 | +1.86 | +4.1% | $45.75 | $47.79 | $45.00 | 1,289,100 | |
| $45.81 | +1.62 | +3.7% | $44.94 | $46.09 | $44.41 | 1,041,700 | |
| $44.19 | -1.85 | -4.0% | $45.66 | $47.14 | $44.18 | 1,426,700 | |
| $46.04 | -0.04 | -0.1% | $45.93 | $46.78 | $45.60 | 1,184,200 | |
| $46.08 | +0.85 | +1.9% | $46.00 | $47.52 | $45.21 | 1,594,800 | |
| $45.23 | -0.20 | -0.4% | $45.04 | $47.52 | $44.47 | 1,696,500 | |
| $45.43 | -3.11 | -6.4% | $49.00 | $49.00 | $45.36 | 1,725,700 | |
| $48.54 | +4.72 | +10.8% | $43.66 | $48.95 | $43.51 | 2,880,200 | |
| $43.82 | +0.46 | +1.1% | $42.95 | $43.86 | $42.25 | 1,525,500 | |
| $43.36 | +1.84 | +4.4% | $41.76 | $43.74 | $41.32 | 1,472,500 | |
| $41.52 | +1.725 | +4.3% | $40.00 | $41.98 | $39.40 | 1,470,500 | |
| $39.80 | -0.775 | -1.9% | $40.41 | $41.05 | $39.55 | 2,667,600 | |
| $40.57 | +2.07 | +5.4% | $39.67 | $40.70 | $38.80 | 1,470,300 | |
| $38.50 | -1.64 | -4.1% | $40.36 | $41.45 | $38.25 | 1,622,100 | |
| $40.14 | -1.07 | -2.6% | $40.83 | $42.36 | $39.10 | 1,760,600 | |
| $41.21 | +0.34 | +0.8% | $41.17 | $41.40 | $40.50 | 1,032,500 | |
| $40.87 | -1.16 | -2.8% | $42.61 | $42.66 | $40.79 | 1,001,600 | |
| $42.03 | -1.83 | -4.2% | $43.18 | $43.78 | $41.64 | 849,400 | |
| $43.86 | +1.41 | +3.3% | $42.79 | $44.20 | $42.39 | 1,450,100 | |
| $42.45 | -0.08 | -0.2% | $41.81 | $43.28 | $41.57 | 962,000 | |
| $42.53 | -2.14 | -4.8% | $44.21 | $44.81 | $42.43 | 992,000 | |
| $44.67 | -0.21 | -0.5% | $45.36 | $45.99 | $44.12 | 673,700 | |
| $44.88 | +1.45 | +3.3% | $43.51 | $45.65 | $43.48 | 1,371,700 | |
| $43.43 | +0.24 | +0.6% | $42.97 | $43.74 | $42.28 | 873,000 | |
| $43.19 | -0.15 | -0.3% | $42.33 | $43.34 | $41.60 | 1,472,100 | |
| $43.34 | -1.91 | -4.2% | $45.21 | $45.55 | $43.32 | 1,684,100 | |
| $45.25 | +0.96 | +2.2% | $44.20 | $45.50 | $44.19 | 1,328,200 | |
| $44.29 | +0.25 | +0.6% | $43.78 | $44.52 | $43.25 | 2,181,500 | |
| $44.04 | +2.57 | +6.2% | $42.01 | $44.10 | $41.81 | 1,155,347 | |
| $41.47 | -0.84 | -2.0% | $42.00 | $42.07 | $41.02 | 1,165,433 | |
| $42.31 | +0.52 | +1.2% | $42.18 | $42.54 | $41.10 | 1,005,500 | |
| $41.79 | -0.40 | -0.9% | $41.67 | $42.45 | $41.05 | 980,400 |
- Ticker
- Lang & Schwarz:A1W7EA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Veracyte Announces Third Quarter 2026 Financial Results
Latest earnings call · Nov 4, 2026
Veracyte (NASDAQ:VCYT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Jul 30, 2026
Q2 2026 Earnings Presentation
Earnings · 23 slides
Latest news
Veracyte Announces Third Quarter 2026 Financial Results
Nov 4, 2026
Closed $24.00 (-54.3%) on Nov 5, 2026
Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026
Nov 2, 2026
Closed $49.00 (-2.0%) on Nov 2, 2026
Veracyte to Participate in Upcoming Investor Conferences
Oct 29, 2026
Closed $50.01 (-4.1%) on Oct 30, 2026
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
Oct 23, 2026
Closed $47.93 (+4.1%) on Oct 23, 2026
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Oct 19, 2026
Closed $43.80 (+1.6%) on Oct 19, 2026
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Oct 16, 2026
Closed $43.12 (-2.9%) on Oct 16, 2026
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
Oct 14, 2026
Closed $44.39 (+2.0%) on Oct 15, 2026
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
Sep 29, 2026
Closed $46.08 (+1.9%) on Sep 29, 2026
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Sep 25, 2026
Closed $45.23 (-0.4%) on Sep 28, 2026
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Sep 14, 2026
Closed $40.14 (-2.6%) on Sep 15, 2026
Veracyte, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 27 in the last 12 months · 261 in all · newest Nov 4, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Nov 4, 2026
- Decks
- 19 decks · latest Jul 30, 2026
Where Veracyte, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VCYT · Home listing | NASDAQ | United States | USD |
| gettex:12V | gettex | Germany | EUR |
| BOATS:VCYT | BOATS | United States | USD |
| LS Exchange:A1W7EA | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1W7EA · This page | Lang & Schwarz | Germany | EUR |
| Tradegate:12V | Tradegate | Germany | EUR |
| Dusseldorf:12V | Dusseldorf | Germany | EUR |
| Frankfurt:12V | Frankfurt | Germany | EUR |
| Munich:12V | Munich | Germany | EUR |
| Hamburg:12V | Hamburg | Germany | EUR |
| Stuttgart:12V | Stuttgart | Germany | EUR |
Valuation
P/E 16.0× against a median of 58.0×: the lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.70B USD
- P/E
- 16.0×
- EV/sales
- 2.9×
- EV/EBITDA
- 14.0×
- Price/book
- 1.4×
- Gross margin
- 72.0%
- Operating margin
- 17.1%
- Net margin
- 21.8%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.34
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Veracyte, Inc. · NASDAQ:VCYT | US$2.03B | US$1.70B | 16.0× | 2.9× | 14.0× | 1.4× | 21.8% | 0.0× | 1.34 |
| Oxford Nanopore Technologies PLC · LSE:ONT | US$2.42B | US$2.23B | n/a | 7.6× | n/a | 4.4× | −64.8% | 0.1× | n/a |
| OneSource Specialty Pharma Limited · NSE:ONESOURCE | US$1.99B | US$2.18B | n/a | 12.0× | 50.9× | 3.1× | −0.1% | 0.3× | n/a |
| Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A · SSE:603456 | US$1.97B | US$1.77B | 22.0× | 2.2× | n/a | 1.5× | 11.3% | 0.0× | n/a |
| Azenta, Inc. · NASDAQ:AZTA | US$1.96B | US$1.63B | n/a | 2.6× | n/a | 1.4× | −26.9% | 0.0× | 1.59 |
| Syngene International Ltd. · NSE:SYNGENE | US$1.96B | US$1.96B | 97.5× | 5.2× | 20.0× | 3.7× | 5.3% | 0.1× | n/a |
| Cohance Lifesciences Ltd · NSE:COHANCE | US$1.91B | US$1.88B | 167× | 8.1× | 55.1× | 4.5× | 5.0% | 0.1× | n/a |
| Alamar Biosciences, Inc. · NASDAQ:ALMR | US$1.84B | US$1.66B | n/a | 14.5× | n/a | 6.1× | −48.2% | 0.1× | 1.70 |
| Fortrea Holdings Inc. · NASDAQ:FTRE | US$1.79B | US$2.62B | n/a | 1.0× | 28.7× | 3.4× | −2.6% | 2.0× | 1.68 |
| ChemoMetec A/S · OMXCOP:CHEMM | US$1.72B | US$1.68B | 58.0× | 22.3× | 40.6× | 16.1× | 39.5% | 0.0× | n/a |
| GemPharmatech Co., Ltd. Class A · SSE:688046 | US$1.65B | US$1.49B | 54.4× | 10.5× | n/a | 4.7× | 21.5% | 0.0× | n/a |
| Median of the others | US$1.93B | US$1.83B | 58.0× | 7.9× | 40.6× | 4.0× | 2.4% | 0.1× | 1.68 |
Forecasts
7 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 41.60 USD · Analysts' mean
- EPS, year to Dec 2026
- 1.94 · 10 analysts
- Revenue, year to Dec 2026
- 590.8M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Marc Stapley | Chief Executive Officer |
| Kevin Haas | Chief Development and Technology Officer |
Board
| Director | Role |
|---|---|
| Robert S. Epstein | Chairman |
| Brent Shafer | Board Member |
| Eliav Barr | Board Member |
| Evan Jones | Board Member |
| Jens Holstein | Board Member |
| Karin Eastham | Board Member |
| Muna Bhanji | Board Member |
| Tom Miller |
Events
Calls
| Call | When | Status |
|---|---|---|
| Veracyte (NASDAQ:VCYT) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q1 2026 Earnings Call | Tue, May 05, 2026 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q4 2025 Earnings Call | Wed, Feb 25, 2026 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q3 2025 Earnings Call | Tue, Nov 04, 2025 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q1 2025 Earnings Call | Wed, May 07, 2025 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q4 2024 Earnings Call | Mon, Feb 24, 2025 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 4:30 PM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −54.3% |
| Q2 2026 | Jul 30, 2026 · After close | −22.5% |
| Q1 2026 | May 5, 2026 · After close | +24.9% |
| Q4 2025 | Feb 25, 2026 | +8.6% |
| Q3 2025 | Nov 4, 2025 · After close | +27.5% |
| Q2 2025 | Aug 6, 2025 · After close | +15.5% |
| Q1 2025 | May 7, 2025 · After close | +1.2% |
| Q4 2024 | Feb 20, 2025 · Before open | −2.5% |
| Q3 2024 | Nov 6, 2024 · After close | +2.0% |
| Q2 2024 | Aug 6, 2024 · After close | +24.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −4.3% |
| Q4 2023 | Feb 22, 2024 · After close | −8.9% |
| Q3 2023 | Nov 7, 2023 · After close | −3.6% |
| Q2 2023 | Aug 8, 2023 · After close | +7.0% |
| Q1 2023 | May 4, 2023 · After close | +4.6% |
| Q4 2022 | Feb 22, 2023 · After close | +0.1% |
| Q3 2022 | Nov 2, 2022 · After close | +24.3% |
| Q2 2022 | Aug 2, 2022 · After close | −6.0% |
| Q1 2022 | May 3, 2022 · After close | +4.6% |
| Q4 2021 | Feb 28, 2022 · After close | +0.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 23 slides | Jul 30, 2026 |
| Investor Presentation (June 2026) | Investor deck | 20 slides | Jun 1, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 22 slides | May 5, 2026 |
| Raymond James Institutional Investor Conference 2026 | Conference | 33 slides | March 2026 |
| Q4 2025 Earnings Presentation | Earnings | 27 slides | Feb 25, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 22 slides | Nov 4, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 24 slides | May 7, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 26 slides | Feb 24, 2025 |
| Q2 2024 Earnings Presentation | Earnings | 15 slides | Aug 6, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 16 slides | May 7, 2024 |
All 19 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q4 2023 Earnings Presentation | Earnings | 16 slides | Feb 22, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 17 slides | Nov 7, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 17 slides | Aug 8, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 17 slides | May 4, 2023 |
| Q1 2022 Earnings Presentation | Earnings | 15 slides | May 3, 2022 |
| Merger or Acquisition (February 2021) | Merger or acquisition | 18 slides | Feb 3, 2021 |
| Merger or Acquisition (February 2021) | Merger or acquisition | 17 slides | Feb 3, 2021 |
| Technical Presentation (2020) | Technical | 7 slides | 2020 |
| Investor Presentation (October 2019) | Investor deck | 17 slides | Oct 22, 2019 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 517.1M | 445.8M | 361.1M | 296.5M | 219.5M | 117.5M | 120.4M | 92.0M | 72.0M | 65.1M |
| Cost of revenue | 157.1M | 147.6M | 112.9M | 101.6M | 74.4M | 41.5M | 36.1M | 33.1M | 28.2M | 25.5M |
| Gross profit | 362.5M | 298.1M | 229.7M | 175.7M | 145.1M | 76.0M | 83.8M | 58.9M | 43.8M | 39.6M |
| Research and development | 70.8M | 69.3M | 57.3M | 40.6M | 29.8M | 17.2M | 14.9M | 14.8M | 13.9M | 15.3M |
| Selling, general and administrative | 110.8M | 178.3M | 157.6M | 76.5M | 101.4M | 36.7M | 29.0M | 24.0M | 23.1M | 23.8M |
| Operating income | 57.8M | 16.1M | -85.8M | -41.1M | -81.9M | -35.4M | -15.1M | -22.2M | -26.5M | -28.8M |
| Depreciation and amortization | 21.4M | 23.5M | 27.2M | 25.9M | 19.6M | 7.94M | 4.12M | 3.92M | 3.84M | 3.51M |
| EBITDA | 79.2M | 39.6M | -58.6M | -15.2M | -62.3M | -27.4M | -11.0M | -18.3M | -22.7M | -25.3M |
| Interest expense | 1.00K | 2.00K | 15.0K | 198.0K | 241.0K | 229.0K | 677.0K | 1.96M | 4.94M | 2.76M |
| Income before tax | 68.2M | 25.7M | -76.6M | -36.4M | -81.6M | -34.9M | -12.6M | -23.0M | -31.0M | -31.4M |
| Income tax | 1.85M | 1.61M | -2.21M | 133.0K | -6.09M | 0 | 0 | 0 | 0 | 0 |
| Net income | 66.4M | 24.1M | -74.4M | -36.6M | -75.6M | -34.9M | -12.6M | -23.0M | -31.0M | -31.4M |
| Earnings per share, basic | 0.84 | 0.32 | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 | -0.62 | -0.91 | -1.09 |
| Earnings per share, diluted | 0.82 | 0.31 | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 | -0.62 | -0.91 | -1.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 362.6M | 239.1M | 216.5M | 154.2M | 173.2M | 349.4M | 159.3M | 78.0M | 33.9M | 59.2M |
| Short-term investments | 50.3M | 50.4M | 0 | 24.6M | 3.96M | 0 | 120.0K | |||
| Receivables | 44.7M | 46.5M | 40.4M | 44.0M | 41.5M | 18.5M | 19.3M | 13.2M | 12.7M | 8.76M |
| Inventory | 20.5M | 21.8M | 16.1M | 14.3M | 11.2M | 4.66M | 6.81M | 3.40M | 5.32M | 3.48M |
| Current assets | 488.4M | 372.3M | 285.6M | 248.6M | 243.1M | 375.7M | 187.7M | 97.0M | 53.9M | 73.6M |
| Property, plant and equipment | 17.7M | 15.1M | 8.99M | 8.93M | 8.94M | 9.69M | 11.5M | |||
| Goodwill | 767.2M | 745.8M | 703.0M | 695.9M | 707.9M | 2.73M | 2.73M | 1.06M | 1.06M | 1.06M |
| Total assets | 1.41B | 1.30B | 1.11B | 1.16B | 1.19B | 457.2M | 275.2M | 120.6M | 78.7M | 101.0M |
| Accounts payable | 4.59M | 8.63M | 12.9M | 11.9M | 12.4M | 3.12M | 2.33M | 2.52M | 3.85M | 2.42M |
| Current liabilities | 59.9M | 78.6M | 61.2M | 62.6M | 64.2M | 16.8M | 17.5M | 13.1M | 12.0M | 11.5M |
| Long-term debt | 0 | 810.0K | 694.0K | 23.9M | 24.9M | 24.9M | ||||
| Total debt | 39.7M | 50.7M | 12.6M | 0 | 1.13M | 810.0K | 694.0K | 25.3M | 24.9M | 24.9M |
| Total liabilities | 96.4M | 124.1M | 70.8M | 81.2M | 91.3M | 35.9M | 35.8M | 40.9M | 41.4M | 41.5M |
| Shareholders' equity | 1.31B | 1.18B | 1.04B | 1.08B | 1.10B | 421.2M | 239.5M | 79.8M | 37.2M | 59.6M |
| Shares outstanding | 79.4M | 77.8M | 73.3M | 72.0M | 71.1M | 58.2M | 49.6M | 40.9M | 33.8M | 33.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 136.3M | 75.1M | 44.2M | 7.54M | -31.6M | -9.71M | -3.23M | -13.5M | -23.9M | -28.0M |
| Capital spending | -9.68M | -11.3M | -9.96M | -8.55M | -5.38M | -2.84M | -2.76M | -1.87M | -1.75M | -4.21M |
| Free cash flow | 126.6M | 63.8M | 34.3M | -1.01M | -37.0M | -12.5M | -5.99M | -15.4M | -25.7M | -32.2M |
| Cash from investing | -9.21M | -56.3M | 15.1M | -29.4M | -739.2M | -3.84M | -42.7M | -1.87M | -1.31M | -4.21M |
| Cash from financing | -4.22M | 4.90M | 2.84M | 3.49M | 596.3M | 203.6M | 127.3M | 59.5M | -218.0K | 52.3M |
| Dividends paid | -3.17M | -3.85M | -977.0K | 0 | 0 | |||||
| Share buybacks | -6.74M | -3.17M | -9.03M | -3.85M | -977.0K | -30.0K | 2.10M | 33.2M | ||
| Change in cash | 123.6M | 23.3M | 62.3M | -18.9M | -176.0M | 190.0M | 81.3M | 44.1M | -25.4M | 20.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Sep 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 14, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 31, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 10, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 6, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Mar 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 16, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 3, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 17, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Veracyte, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 80,695,480
- Fully diluted
- 80,695,480
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 80,695,480 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 80,695,480 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Tina Susan Nova Other companies: Aurinia Pharmaceuticals Inc (Director · Since at least May 15, 2025); Azenta, Inc. (Director · Since at least Feb 3, 2023); Exagen Inc. (Director · Since at least Sep 18, 2019); CapForce Inc. (Director · Apr 24, 2017 – Sep 2, 2019 · Past); NanoString Technologies Inc (Director · Apr 29, 2014 – Apr 29, 2014 · Past); DMK Pharmaceuticals Corporation (Director · Feb 10, 2011 – Oct 16, 2013 · Past); Genoptix Inc (President and CEO, Director · Oct 29, 2007 – Mar 7, 2011 · Past); Cypress Bioscience Inc (Director · Apr 26, 2007 – Jan 4, 2010 · Past); Arena Pharmaceuticals Inc (Director · Jul 28, 2006 – Mar 11, 2022 · Past) | President, CLIA U.S. · Nov 12, 2015 – Mar 3, 2022 · Past |
| John Bishop Other companies: Ardelyx, Inc. (Chief Technical and Quality Officer · Since at least Aug 1, 2025); Lyra Therapeutics, Inc. (Chief Technology Officer · Feb 27, 2023 – Jan 30, 2024 · Past); Forma Therapeutics Holdings Inc (SVP, Chief Technology Officer · Jun 14, 2021 – Oct 14, 2022 · Past); Cepheid (Chairman of the Board and CEO, Director · Feb 26, 2009 – Nov 4, 2016 · Past); Conceptus Inc (Director · Feb 25, 2009 – Jun 5, 2013 · Past); Momenta Pharmaceuticals Inc (Senior VP, Pharmaceutical Scie · Feb 17, 2006 – May 19, 2016 · Past) | Director · Dec 1, 2014 – Jul 17, 2023 · Past |
| Jesse I Treu Other companies: CoLucid Pharmaceuticals Inc (Director · May 5, 2015 – May 11, 2015 · Past); Aldeyra Therapeutics, Inc. (Director · May 1, 2014 – Jun 9, 2020 · Past); Tandem Diabetes Care, Inc. (Director · Nov 13, 2013 – Nov 15, 2016 · Past); Tobira Therapeutics Inc (Director · Aug 21, 2013 – Jan 1, 2015 · Past); Somaxon Pharmaceuticals Inc (Director · Mar 3, 2010 – Jun 9, 2010 · Past) | Director · Oct 29, 2013 – Feb 28, 2019 · Past |
| Brook H Byers Other companies: CareDx, Inc. (Director · Jul 16, 2014 – Apr 1, 2016 · Past); Foundation Medicine Inc (Director · Sep 24, 2013 – Apr 7, 2015 · Past); Pacific Biosciences of California, Inc. (Director · Oct 26, 2010 – May 17, 2016 · Past); Genomic Health Inc (Director · May 25, 2006 – Apr 1, 2011 · Past) | Director · Oct 29, 2013 – May 20, 2014 · Past |
| Evan Jones Other companies: CapForce Inc. (Director · May 4, 2015 – May 17, 2021 · Past); Foundation Medicine Inc (Director · Sep 24, 2013 – Jul 31, 2018 · Past); CAS Medical Systems Inc (Director · Jun 20, 2012 – Jun 24, 2013 · Past); Standard BioTools Inc. (Director · Dec 12, 2011 – Jul 31, 2017 · Past) | Board Member · Since at least Oct 29, 2013 |
| Karin Eastham Other companies: Personalis, Inc. (Chair · Since at least Sep 9, 2019); Nektar Therapeutics (Director · Sep 27, 2018 – Sep 16, 2022 · Past); Geron Corporation (Director · May 17, 2016 – Jan 13, 2023 · Past); Illumina, Inc. (Director · May 17, 2016 – May 28, 2019 · Past) | Board Member · Since at least Jun 20, 2016 |
| Kevin Gordon Other companies: Progyny, Inc. (Director · Since at least Oct 24, 2019); IQVIA Holdings, Inc. (EVP and COO · May 8, 2013 – Jun 9, 2016 · Past); Teleflex Incorporated (Exec. Vice Pres. & CFO · Dec 25, 2005 – Dec 31, 2009 · Past) | Director · Dec 12, 2016 – Jun 8, 2022 · Past |
| Muna Bhanji Other companies: Intellia Therapeutics, Inc. (Independent Director · Since at least Apr 28, 2022); Ardelyx, Inc. (Director · Since at least Mar 11, 2021); Cytokinetics, Incorporated (Director · Since at least Feb 17, 2021) | Director · Since at least Mar 19, 2021 |
| Rebecca Chambers Other companies: Alamar Biosciences, Inc. (Director · Since at least Apr 16, 2026); Inari Medical Inc (Director · Jun 21, 2021 – Feb 19, 2025 · Past); Outset Medical, Inc. (Chief Financial Officer · Sep 14, 2020 – Jun 24, 2021 · Past) | Chief Financial Officer · Since at least Jul 19, 2021 |
| Brent Shafer Other companies: Tactile Systems Technology, Inc. (Director · Since at least Nov 5, 2026); Baxter International Inc. (Chair of the Board, Former Chair · Since at least May 4, 2026) | Board Member · Since at least Nov 6, 2024 |
All 28 people
| Person | Seat |
|---|---|
| David Brent Shafer Other companies: Tactile Systems Technology, Inc. (Director · Since at least May 6, 2026); Baxter International Inc. (Director · Since at least May 5, 2026) | Director · Since at least Jun 11, 2026 |
| Keith Kennedy Other companies: CareDx, Inc. (Chief Financial Officer and Chief Operating Officer · Since at least Sep 12, 2024); MCG Capital Corp (President and CEO, Director · Aug 14, 2015 – Aug 18, 2015 · Past) | COO / CFO · Dec 6, 2016 – Mar 2, 2021 · Past |
| Beverly Jane Alley Other companies: MCG Capital Corp (CFO · Mar 15, 2012 – Aug 18, 2015 · Past) | VP, Corporate Controller · Apr 1, 2021 – May 17, 2021 · Past |
| Bonnie H Anderson Other companies: Bruker Corporation (Director · Since at least Jan 5, 2023) | Director · May 1, 2022 – Jun 2, 2023 · Past |
| Christopher Hall Other companies: Personalis, Inc. (Director · Since at least Dec 31, 2022) | President and COO · Jul 22, 2015 – Jun 3, 2019 · Past |
| Kevin Haas Other companies: Myriad Genetics, Inc. (Chief Technology Officer · Since at least Feb 2, 2026) | Chief Development and Technology Officer · Since at least Mar 16, 2026 |
| Marc A. Stapley Other companies: Glaukos Corporation (Director · Since at least May 30, 2019) | Chief Executive Officer, Director · Since at least Jun 1, 2021 |
| Phillip G Febbo Other companies: Illumina, Inc. (SVP Chief Medical Officer · Apr 5, 2022 – Mar 1, 2023 · Past) | Chief Scientific & Med Officer · Since at least Oct 2, 2023 |
| Robert S. Epstein Other companies: Fate Therapeutics, Inc. (Board Member · Since at least May 5, 2026) | Director · Since at least May 20, 2026 |
| Annie McGuire | EVP, General Counsel · Since at least Feb 28, 2022 |
| Eliav Barr | Board Member · Since at least Aug 9, 2022 |
| Giulia C Kennedy | Chief Scientific & Med Officer · Feb 21, 2019 – Dec 6, 2022 · Past |
| Jens Holstein | Board Member · Since at least Jun 18, 2025 |
| John Leite | Global Chief Commercial Off · Since at least Sep 1, 2023 |
| Jonathan Wygant | VP, Chief Accounting Officer · Since at least Aug 5, 2022 |
| Marc Stapely | Until Sep 4, 2026 · Past |
| Thomas F Miller | Director · Since at least Sep 3, 2024 |
| Tom Miller | Director · Since at least Nov 6, 2024 |
Log in to ask 6ix AI your own questions about Veracyte, Inc.